CME / ABIM MOC / CE

Myeloma, Lymphoma, and Benign Hematology

Authors: Hagop M. Kantarjian, MD; Sagar Lonial, MD, FACP; S. Vincent Rajkumar, MD; Loretta Nastoupil, MD; Julie Vose, MD, MBA; Stephan Moll, MD
CME / ABIM MOC / CE Released: 2/24/2023
Valid for credit through: 2/24/2024

Credits Available

Physicians - maximum of 2.00 AMA PRA Category 1 Credit(s)™

ABIM Diplomates - maximum of 2.00 ABIM MOC points

Nurses - 2.00 ANCC Contact Hour(s) (2 contact hours are in the area of pharmacology)

Pharmacists - 2.00 Knowledge-based ACPE (0.200 CEUs)

You Are Eligible For
- Letter of Completion
- ABIM MOC points

Target Audience and Goal Statement

This activity is intended for hematologists/oncologists, nurses, nurse practitioners (NPs), pharmacists, and other healthcare practitioners (HCPs) involved in the care of patients with hematological malignancies and disorders.

The goal of this activity is for learners to be better able to manage care for patients with hematologic malignancies by incorporating updates on the most meaningful and practice-changing data in hematology from 2022.

Upon completion of this activity, participants will:

Have increased knowledge regarding the
- Emerging clinical trial data for hematologic malignancies
- Methods to assess treatment response in patients with hematologic malignancies and disorders
- Treatment-related adverse events of agents used for hematologic malignancies and disorders
Demonstrate greater confidence in their ability to
- Individualize treatment for patients with hematologic malignancies and disorders

Disclosures

Medscape, LLC requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated. Others involved in the planning of this activity have no relevant financial relationships.

Disclosures for additional planners can be found here.

Faculty

Hagop M. Kantarjian, MD

Professor and Chair
Department of Leukemia
Samsung Distinguished University Chair in Cancer Medicine
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Disclosures

Hagop M. Kantarjian, MD, has no relevant financial relationships.

Sagar Lonial, MD, FACP

Chair and Professor
Department of Hematology and Medical Oncology
Chief Medical Officer
Winship Cancer Institute of Emory University
Atlanta, Georgia

Disclosures

The opinions expressed are those of Dr Sagar Lonial and do not necessarily reflect the views of Emory University or Emory Healthcare. Dr Sagar Lonial’s participation in this activity does not constitute or imply endorsement by Emory University or Emory Healthcare.

Sagar Lonial, MD, FACP, has the following relevant financial relationships:
Consultant or advisor for: AbbVie, Inc.; Amgen, Inc.; Bristol Myers Squibb Company; Celgene Corporation; Genentech, Inc.; GlaxoSmithKline; Janssen; Novartis; Takeda
Research funding from: Bristol Myers Squibb Company; Janssen; Novartis; Takeda
Owns stock (publicly traded) in: TG Therapeutics, Inc.
Other: Board of Directors for: TG Therapeutics, Inc.

S. Vincent Rajkumar, MD

Edward W. and Betty Knight Scripps
Professor of Medicine
Mayo Clinic
Rochester, Minnesota

Disclosures

S. Vincent Rajkumar, MD, has no relevant financial relationships.

Loretta Nastoupil, MD

Deputy Chair
Section Chief, Indolent Lymphoma and New Drug Development
Director, Lymphoma Outcomes Database
The University of Texas
MD Anderson Cancer Center
Houston, Texas

Disclosures

Loretta Nastoupil, MD, has the following relevant financial relationships:
Consultant or advisor for: ADC Therapeutics; Bristol Myers Squibb Company; Caribou Biosciences; Epizyme; Genentech; Gilead Sciences, Inc.; Janssen; Kite Pharma, Inc.; MorphoSys; Novartis; Roche; SIRPant Immunotherapeutics; Takeda
Research funding from: Bristol Myers Squibb Company; Caribou Biosciences; Epizyme; Genentech; Gilead Sciences, Inc.; Janssen; Kite Pharma, Inc.; Novartis; Roche; Takeda

Julie Vose, MD, MBA

Chief, Hematology/Oncology Division
University of Nebraska Medical Center
Buffett Cancer Center
Omaha, Nebraska

Disclosures

Julie Vose, MD, MBA, has the following relevant financial relationships:
Consultant or advisor for: AbbVie, Inc.; Daiichi Sankyo, Inc.; Genentech; Lilly; Novartis; Seagen Inc.
Research funding from: Bristol Myers Squibb Company; Epizyme; Loxo Oncology; Novartis

Stephan Moll, MD

Professor of Medicine
University of North Carolina School of Medicine
Chapel Hill, North Carolina

Disclosures

Stephan Moll, MD, has the following relevant financial relationships:
Consultant or advisor for: Bristol Myers Squibb Company; Diagnostica Stago, Inc.

Editor

John Churchwell, PhD

Medical Education Director, Medscape, LLC

Disclosures

John Churchwell, PhD, has the following relevant financial relationships:
Employed by an ineligible company: Medtronic (former)

Compliance Reviewer/Nurse Planner

Leigh Schmidt, MSN, RN, CNE, CHCP

Associate Director, Accreditation and Compliance, Medscape, LLC

Disclosures

Leigh Schmidt, MSN, RN, CNE, CHCP, has no relevant financial relationships.

Peer Reviewer

This activity has been peer reviewed and the reviewer has no relevant financial relationships.

Accreditation Statements

In support of improving patient care, Medscape, LLC is jointly accredited with commendation by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

For Physicians

Medscape, LLC designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Contact This Provider

For Nurses

Awarded 2.0 contact hour(s) of nursing continuing professional development for RNs and APNs; 2.0 contact hours are in the area of pharmacology.

Contact This Provider

For Pharmacists

Medscape, LLC designates this continuing education activity for 2.0 contact hour(s) (0.200 CEUs) (Universal Activity Number JA0007105-0000-23-015-H01-P).

Contact This Provider

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]

Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information on applicability and acceptance of continuing education credit for this activity, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 70% on the post-test.

Follow these steps to earn CME/CE credit*:

Read about the target audience, learning objectives, and author disclosures.
Study the educational content online or print it out.
Online, choose the best answer to each test question. To receive a certificate, you must receive a passing score as designated at the top of the test. We encourage you to complete the Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate, but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period, you can print out the tally as well as the certificates from the CME/CE Tracker.

*The credit that you receive is based on your user profile.

From Medscape Education Oncology

CME / ABIM MOC / CE

Myeloma, Lymphoma, and Benign Hematology

Authors: Hagop M. Kantarjian, MD; Sagar Lonial, MD, FACP; S. Vincent Rajkumar, MD; Loretta Nastoupil, MD; Julie Vose, MD, MBA; Stephan Moll, MDFaculty and Disclosures

CME / ABIM MOC / CE Released: 2/24/2023

Valid for credit through: 2/24/2024

processing....

Contents of This CME Activity

All sections of this activity are required for credit.

Newly Diagnosed Multiple Myeloma

What are the latest advances in the management of newly diagnosed multiple myeloma?
Sagar Lonial, MD, FACP

Relapsed/Refractory Multiple Myeloma

What are the latest updates in CAR T-cell therapies, bispecific T-cell engagers, and novel therapies?
S. Vincent Rajkumar, MD

Hodgkin and Indolent Non-Hodgkin Lymphoma

Dr Nastoupil explores the latest data in Hodgkin and indolent non-Hodgkin lymphoma.
Loretta Nastoupil, MD

Aggressive Non-Hodgkin Lymphoma

Dr Vose looks at the newest advances in aggressive NHL.
Julie Vose, MD, MBA

Benign Hematology

Dr Moll explores the latest management of various benign hematologic disorders.
Stephan Moll, MD

Educational Impact Challenge

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.

Page 1 of 8

CME / ABIM MOC / CE Information Download Slides

Print
Like Tweet

Disclaimer

The educational activity presented above may involve simulated, case-based scenarios. The patients depicted in these scenarios are fictitious and no association with any actual patient, whether living or deceased, is intended or should be inferred.

The material presented here does not necessarily reflect the views of Medscape, LLC, or any individuals or commercial entities that support companies that support educational programming on medscape.org. These materials may include discussion of therapeutic products that have not been approved by the US Food and Drug Administration, off-label uses of approved products, or data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal. Readers should verify all information and data before treating patients or employing any therapies described in this or any educational activity. A qualified healthcare professional should be consulted before using any therapeutic product discussed herein.

Faculty and Disclosures

Faculty

Hagop M. Kantarjian, MD

Sagar Lonial, MD, FACP

S. Vincent Rajkumar, MD

Loretta Nastoupil, MD

Julie Vose, MD, MBA

Stephan Moll, MD

Editor

John Churchwell, PhD

Compliance Reviewer/Nurse Planner

Leigh Schmidt, MSN, RN, CNE, CHCP

Peer Reviewer

CME / ABIM MOC / CE

Myeloma, Lymphoma, and Benign Hematology

Credits Available

You Are Eligible For

Target Audience and Goal Statement

Disclosures

Faculty

Hagop M. Kantarjian, MD

Sagar Lonial, MD, FACP

S. Vincent Rajkumar, MD

Loretta Nastoupil, MD

Julie Vose, MD, MBA

Stephan Moll, MD

Editor

John Churchwell, PhD

Compliance Reviewer/Nurse Planner

Leigh Schmidt, MSN, RN, CNE, CHCP

Peer Reviewer

Accreditation Statements

For Physicians

For Nurses

For Pharmacists

Instructions for Participation and Credit

Myeloma, Lymphoma, and Benign Hematology

Contents of This CME Activity

Newly Diagnosed Multiple Myeloma

Relapsed/Refractory Multiple Myeloma

Hodgkin and Indolent Non-Hodgkin Lymphoma

Aggressive Non-Hodgkin Lymphoma

Benign Hematology

Educational Impact Challenge